20


nanotimes


Companies Facts


for rapid detection and grading of various multiple cancers using blood assays, with higher accuracy and at less cost than current single ELISA assays. All diagnostic and pharmaceutical products will inclu- de QMC quantum dots functionalized by Nanoaxis biomedical IP nanotechnology.


http://www.qdotss.com Q


uantuMDx Group Limited has signed an exclusive license agreement with Nanosys


Inc., an advanced materials architect, for several patents and patent applications related to the use of nanostructures for biosensors. The core intellectual property involves the use of nanowires and nano- tubes in biosensors, including field effect transistors (FETs) biosensors, which were derived from the work of Prof. Charles Lieber, a professor of chemistry at Harvard and pioneer in nanotechnology.


Under terms of the agreement, QuantuMDx has secured exclusive worldwide rights for the use of nanostructures for DNA sequencing and, amongst others, detecting nucleic acid biomarkers associ- ated with disease. In exchange, Nanosys has recei- ved an upfront license fee and downstream royalty payments. No other financial details of the deal were disclosed.


QuantuMDx Group’s medical director, Professor Sir John Burn, went on to say “We are creating a simple to use, sample to result device which will provide ro- bust, handheld, clinical DNA sequencing at the point of care. The technology is cheap by any measure and with turnaround times in the minutes, it will be an exciting and significant new instrument in the clinical


Advertisement


Too fast for a photo: the new µsprint


11-09 :: September 2011


sec


Typical measurement system: >180 sec µsprint: 1 sec


NanoFocus AG Lindnerstrasse 98 | 46149 Oberhausen Phone +49 (0) 208-62 000-0 | Fax +49 (0) 208-62 000 info@nanofocus.de | www.nanofocus.de WKN: 540066 | ISIN: DE 0005400667


NF10030


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67